WO2006024367A3 - Use of nkg2d receptor/nkg2d ligand interaction blockers in the treatment of auto-immune diseases - Google Patents

Use of nkg2d receptor/nkg2d ligand interaction blockers in the treatment of auto-immune diseases Download PDF

Info

Publication number
WO2006024367A3
WO2006024367A3 PCT/EP2005/008579 EP2005008579W WO2006024367A3 WO 2006024367 A3 WO2006024367 A3 WO 2006024367A3 EP 2005008579 W EP2005008579 W EP 2005008579W WO 2006024367 A3 WO2006024367 A3 WO 2006024367A3
Authority
WO
WIPO (PCT)
Prior art keywords
soluble
nkg2d
blockers
ligand interaction
receptor
Prior art date
Application number
PCT/EP2005/008579
Other languages
German (de)
French (fr)
Other versions
WO2006024367A2 (en
Inventor
Alexander Steinle
Manuel Friese
Heinz Wiendl
Michael Weller
Bettina Schreiner
Robert Weissert
Original Assignee
Univ Eberhard Karls
Alexander Steinle
Manuel Friese
Heinz Wiendl
Michael Weller
Bettina Schreiner
Robert Weissert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Eberhard Karls, Alexander Steinle, Manuel Friese, Heinz Wiendl, Michael Weller, Bettina Schreiner, Robert Weissert filed Critical Univ Eberhard Karls
Priority to EP05773900A priority Critical patent/EP1848452A2/en
Publication of WO2006024367A2 publication Critical patent/WO2006024367A2/en
Publication of WO2006024367A3 publication Critical patent/WO2006024367A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of NKG2D receptor/NKG2D ligand interaction blockers for producing a medicament for treating auto-immune diseases, especially multiple sclerosis, and for blocking the NKG2D receptor, said blockers being selected from the group containing soluble NKG2D receptors, soluble MICA, soluble MICB, soluble ULBP1, soluble ULBP2, soluble ULBP3, soluble ULBP4, soluble RAET1L, soluble RAET1G, and allelic variants or fragments or derivatives of said blockers. The invention also relates to synthetically produced NKG2D receptor/NKG2D ligand interaction blockers.
PCT/EP2005/008579 2004-08-30 2005-08-08 Use of nkg2d receptor/nkg2d ligand interaction blockers in the treatment of auto-immune diseases WO2006024367A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05773900A EP1848452A2 (en) 2004-08-30 2005-08-08 Use of nkg2d receptor/nkg2d ligand interaction blockers in the treatment of auto-immune diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004042894.8 2004-08-30
DE102004042894A DE102004042894A1 (en) 2004-08-30 2004-08-30 Use of blockers of NKG2D receptor / NKG2D ligand interaction in autoimmune diseases

Publications (2)

Publication Number Publication Date
WO2006024367A2 WO2006024367A2 (en) 2006-03-09
WO2006024367A3 true WO2006024367A3 (en) 2006-06-15

Family

ID=35462321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/008579 WO2006024367A2 (en) 2004-08-30 2005-08-08 Use of nkg2d receptor/nkg2d ligand interaction blockers in the treatment of auto-immune diseases

Country Status (3)

Country Link
EP (1) EP1848452A2 (en)
DE (1) DE102004042894A1 (en)
WO (1) WO2006024367A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5591712B2 (en) 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー／エス Antibodies against human NKG2D and uses thereof
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
WO2012091756A1 (en) * 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
CA2823297C (en) * 2010-12-30 2021-05-25 Avidbiotics Corp. Non-natural mic proteins
EP2970490A4 (en) 2013-03-15 2017-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
US11066471B2 (en) 2016-10-19 2021-07-20 Novelogics Biotechnology Inc. Antibodies to MICA and MICB proteins
CN112500497B (en) * 2020-12-14 2021-06-08 南京凯地医疗技术有限公司 CLTX-NKG2D bispecific chimeric antigen receptor cell and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029436A2 (en) * 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300919A2 (en) * 2000-03-24 2003-07-28 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029436A2 (en) * 2001-10-04 2003-04-10 Immunex Corporation Ul16 binding protein 4

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BACKSTROM E ET AL: "Activation of natural killer cells: Underlying molecular mechanisms revealed", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 60, no. 1-2, 1 August 2004 (2004-08-01), pages 14 - 22, XP002360676, ISSN: 0300-9475 *
OGASAWARA KOUETSU ET AL: "NKG2D blockade prevents autoimmune diabetes in NOD mice", IMMUNITY, vol. 20, no. 6, June 2004 (2004-06-01), pages 757 - 767, XP002360662, ISSN: 1074-7613 *
STEINLE ALEXANDER ET AL: "Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family", IMMUNOGENETICS, vol. 53, no. 4, May 2001 (2001-05-01), pages 279 - 287, XP002360705, ISSN: 0093-7711 *
WIEMANN K ET AL: "Danger-detector NKG2D: Immunosurveillance of induced self and modulation by cytokines and soluble ligands", CURRENT MEDICINAL CHEMISTRY - ANTI-INFLAMMATORY & ANTI-ALLERGY AGENTS, vol. 4, no. 2, April 2005 (2005-04-01), pages 141 - 152, XP008057752, ISSN: 1568-0142 *

Also Published As

Publication number Publication date
WO2006024367A2 (en) 2006-03-09
DE102004042894A1 (en) 2006-03-02
EP1848452A2 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
WO2006024367A3 (en) Use of nkg2d receptor/nkg2d ligand interaction blockers in the treatment of auto-immune diseases
NZ615012A (en) Combinatorial therapy involving alpha5beta1 antagonists
WO2006014618A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
WO2007147090A3 (en) Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
WO2005048935A3 (en) Methods of modulating immunity
EP1135477A4 (en) Humanized monoclonal antibodies
WO2006013472A3 (en) Novel anti-igf-ir antibodies and uses thereof
WO2004009015A3 (en) Combination therapy for the treatment of obesity
UA95304C2 (en) Use of dll4 antagonists for the prevention of vascular disorders
WO2004050039A3 (en) Spirocyclic ureas, compositions containing such compounds and methods of use
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2005058967A8 (en) Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
WO2003013537A3 (en) Irinotecan for treatment of cancer
WO2008140653A3 (en) Humaneered anti-factor b antibody
WO2005046661A3 (en) Use of nitric oxide donors for the treatment of drug addiction
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
WO2006048450A3 (en) Peptides for use in the treating obesity
WO2006048452A3 (en) Peptides for use in treating of obesity
WO2006034491A3 (en) Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
NO20015413L (en) Use of dopamine D3 receptor ligands for the manufacture of medicaments for the treatment of renal dysfunction
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
MXPA04004745A (en) Partial dopamine-d2.
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2005773900

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005773900

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005773900

Country of ref document: EP